Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.

Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M.

Cancer Res. 2013 Jan 1;73(1):406-16. doi: 10.1158/0008-5472.CAN-12-1733. Epub 2012 Nov 7.

2.

Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.

Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z.

Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. doi: 10.1016/j.bbrc.2014.01.164. Epub 2014 Feb 3.

PMID:
24502949
3.
4.

Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.

Yu L, Fan Z, Fang S, Yang J, Gao T, Simões BM, Eyre R, Guo W, Clarke RB.

Oncotarget. 2016 May 31;7(22):33055-68. doi: 10.18632/oncotarget.8849.

5.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

6.

Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.

Lundholm L, Hååg P, Zong D, Juntti T, Mörk B, Lewensohn R, Viktorsson K.

Cell Death Dis. 2013 Jan 31;4:e478. doi: 10.1038/cddis.2012.211.

7.

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

Ma L, Lai D, Liu T, Cheng W, Guo L.

Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602. doi: 10.1093/abbs/gmq067. Epub 2010 Aug 12.

PMID:
20705681
8.

Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.

Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ, O'Byrne KJ.

PLoS One. 2013;8(1):e54193. doi: 10.1371/journal.pone.0054193. Epub 2013 Jan 17.

9.

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.

Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K.

Cancer Sci. 2013 Jan;104(1):78-84. doi: 10.1111/cas.12045. Epub 2012 Nov 24.

10.

CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.

Alama A, Gangemi R, Ferrini S, Barisione G, Orengo AM, Truini M, Bello MG, Grossi F.

Arch Immunol Ther Exp (Warsz). 2015 Jun;63(3):207-14. doi: 10.1007/s00005-015-0330-5. Epub 2015 Feb 13.

PMID:
25678473
11.

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

12.

Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling.

Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, Shay JW, Wistuba II, Minna JD.

Cancer Res. 2010 Dec 1;70(23):9937-48. doi: 10.1158/0008-5472.CAN-10-0881. Epub 2010 Nov 30.

13.

HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.

Xu Y, Jiang Z, Zhang Z, Sun N, Zhang M, Xie J, Li T, Hou Y, Wu D.

J Cell Biochem. 2014 Jun;115(6):1112-21. doi: 10.1002/jcb.24751.

PMID:
24356998
14.

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY.

Oncogene. 2008 Mar 13;27(12):1749-58. Epub 2007 Sep 24.

PMID:
17891174
15.

Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.

Wang L, Liu X, Ren Y, Zhang J, Chen J, Zhou W, Guo W, Wang X, Chen H, Li M, Yuan X, Zhang X, Yang J, Wu C.

Cell Death Dis. 2017 Apr 13;8(4):e2746. doi: 10.1038/cddis.2016.409.

16.

Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.

Wang M, Ma X, Wang J, Wang L, Wang Y.

Int J Oncol. 2014 Apr;44(4):1401-9. doi: 10.3892/ijo.2014.2301. Epub 2014 Feb 14.

PMID:
24535252
17.

Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.

Su J, Wu S, Tang W, Qian H, Zhou H, Guo T.

Mol Carcinog. 2016 Nov;55(11):1822-1832. doi: 10.1002/mc.22430. Epub 2015 Oct 29.

PMID:
26513225
18.

Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.

Ai Z, Pan H, Suo T, Lv C, Wang Y, Tong S, Liu H.

Cancer Lett. 2011 Nov 28;310(2):181-7. doi: 10.1016/j.canlet.2011.06.035. Epub 2011 Jul 5.

PMID:
21788103
19.

Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.

Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS.

Mol Med. 2011 Jan-Feb;17(1-2):103-12. doi: 10.2119/molmed.2010.00062. Epub 2010 Oct 15.

20.

Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line.

Chen L, Chang WC, Hung YC, Chang YY, Bao BY, Huang HC, Chung WM, Shyr CR, Ma WL.

Reprod Sci. 2014 Mar;21(3):386-94. doi: 10.1177/1933719113497281. Epub 2013 Aug 20.

Supplemental Content

Support Center